Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Soleno Therapeutics ( NASDAQ:SLNO )
SLNO shares fall 9.68% after Scorpion Capital calls Vykat XR unsafe and overpriced. The report warns that Soleno's stock could drop back to penny-stock territory. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
How Much Upside is Left in Soleno Therapeutics ( SLNO ) ? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Soleno Therapeutics ( SLNO ) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Soleno ( SLNO ) Q2 Revenue Jumps 30%
Soleno Therapeutics ( NASDAQ:SLNO ) , a biotech company focused on rare disease treatments, posted its inaugural commercial revenue following the U.S. launch of VYKAT XR for Prader-Willi syndrome ( PWS ) . In its earnings release on August 6, 2025, the company reported GAAP revenue of $32.7 ...
Soleno Therapeutics, Inc. ( SLNO ) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Soleno Therapeutics, Inc. ( SLNO ) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Soleno Therapeutics ( SLNO ) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Could Help Soleno Therapeutics ( SLNO ) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering ...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq:SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common ...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the ...
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress - Aardvark Therapeutics ( NASDAQ:AARD )
Aardvark's IPO raised $94.2 million at $16/share; funds expected to support operations into 2027. HC Wainwright initiated coverage with Buy rating, sets $40 price forecast of AARD. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
Soleno Therapeutics Highlights New Data on VYKAT ( TM ) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 25, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR ( diazoxide choline ) extended-release tablets, previously ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In Hope: International ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation Conference is the first-ever international meeting jointly hosted by the ...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application ( MAA ) seeking regulatory approval ...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application ( MAA ) seeking ...
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT ( TM ) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 20, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc.
Soleno Therapeutics Announces Presentations Featuring VYKAT ( TM ) XR in Prader-Willi Syndrome at ISPOR 2025 - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 13, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden of Prader-Willi syndrome ( PWS ) and findings ...
Soleno Therapeutics Announces VYKAT ( TM ) XR Launch - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., April 14, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR ( diazoxide choline ) extended-release ...
Soleno Therapeutics Announces VYKAT ( TM ) XR Launch
First prescriptions delivered to individuals with PWS First prescriptions delivered to individuals with ...
Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday - BILL Holdings ( NYSE:BILL ) , Agnico Eagle Mines ( NYSE:AEM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna cut Saia, Inc. SAIA price target from $540 to $410.
Soleno Shares Are Up Today: What's Going On? - Soleno Therapeutics ( NASDAQ:SLNO )
Soleno Therapeutics shares jumped 37.2% after securing FDA approval for Vykat XR, its first commercial drug for treating hyperphagia. The approval was based on Phase 3 trial data showing significant effectiveness, with the drug expected to launch in the U.S. by April 2025.
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Dermata Therapeutics ( NASDAQ:DRMA ) , Auddia ( NASDAQ:AUUD )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 90 points on Thursday. The Dow traded down 0.23% to 42,358.68 while the NASDAQ fell 0.05% to 17,890.40. The S&P 500 also fell, dropping, 0.04% to 5,709.99. Consumer discretionary shares jumped by 1.2% on ...
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr ( NASDAQ:CAR ) , Concentrix ( NASDAQ:CNXC )
U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday. Shares of Concentrix Corporation CNXC rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Soleno Therapeutics ( NASDAQ:SLNO )
Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics SLNO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Why Is Soleno Therapeutics Soaring On Thursday? - Soleno Therapeutics ( NASDAQ:SLNO )
FDA approved Soleno's Vykat XR, the first therapy for hyperphagia in Prader-Willi syndrome, for patients aged 4 and older. Soleno plans to launch Vykat XR in the U.S. by April 2025, supported by a strong commercial strategy and medical education efforts. Feel unsure about the market's next move?
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc.
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT ( TM ) XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome ...
What the Options Market Tells Us About Soleno Therapeutics - Soleno Therapeutics ( NASDAQ:SLNO )
Investors with a lot of money to spend have taken a bullish stance on Soleno Therapeutics SLNO. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance ...
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper ...
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at ...
What the Options Market Tells Us About Soleno Therapeutics - Soleno Therapeutics ( NASDAQ:SLNO )
Whales with a lot of money to spend have taken a noticeably bullish stance on Soleno Therapeutics. Looking at options history for Soleno Therapeutics SLNO we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with ...
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release ( DCCR ) Tablets in Prader-Willi Syndrome at ESPE 2024 - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., Nov. 14, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development ...
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval.
Soleno Therapeutics's Options Frenzy: What You Need to Know - Soleno Therapeutics ( NASDAQ:SLNO )
Whales with a lot of money to spend have taken a noticeably bearish stance on Soleno Therapeutics. Looking at options history for Soleno Therapeutics SLNO we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with ...
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday - PepsiCo ( NASDAQ:PEP )
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Tuesday. Shares of PepsiCo, Inc. PEP rose during Tuesday's session following the release of quarterly results. PepsiCo reported mixed third-quarter results and lowered its 2024 organic revenue guidance.
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday - Hain Celestial Group ( NASDAQ:HAIN )
U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday. Shares of The Hain Celestial Group, Inc. HAIN shares gained 34.2% to $9.16 after the company reported better-than-expected fourth-quarter adjusted EPS results.
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR ( Diazoxide Choline ) Extended-Release Tablets in Prader-Willi Syndrome
PDUFA target action date set for December ...
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR ( Diazoxide Choline ) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., June 28, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application ( NDA ) to the ...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
REDWOOD CITY, Calif., June 24, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of ...
Soleno Therapeutics Set to Join Russell 3000® Index - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 04, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the ...
Soleno Therapeutics Announces Oral Presentation featuring DCCR ( Diazoxide Choline ) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 22, 2024 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR ...
